These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8925396)

  • 1. Pharmacokinetic differences between ocular inserts and eyedrops.
    Friedrich SW; Saville BA; Cheng YL; Rootman DS
    J Ocul Pharmacol Ther; 1996; 12(1):5-18. PubMed ID: 8925396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application site dependent ocular absorption of timolol.
    Urtti A; Sendo T; Pipkin JD; Rork G; Repta AJ
    J Ocul Pharmacol; 1988; 4(4):335-43. PubMed ID: 3246568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans.
    Urtti A; Rouhiainen H; Kaila T; Saano V
    Pharm Res; 1994 Sep; 11(9):1278-82. PubMed ID: 7816756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of epinephrine pretreatment and solution pH on ocular and systemic absorption of ocularly applied timolol in rabbits.
    Kyyrönen K; Urtti A
    J Pharm Sci; 1990 Aug; 79(8):688-91. PubMed ID: 2231330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of drug release rate on systemic timolol absorption from polymeric ocular inserts in the pigmented rabbit.
    Lee VH; Li SY; Sasaki H; Saettone MF; Chetoni P
    J Ocul Pharmacol; 1994; 10(2):421-9. PubMed ID: 8083561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved ocular: systemic absorption ratio of timolol by viscous vehicle and phenylephrine.
    Kyyrönen K; Urtti A
    Invest Ophthalmol Vis Sci; 1990 Sep; 31(9):1827-33. PubMed ID: 2211028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraocular pressure reduction and systemic absorption of timolol after administration of one side-coated inserts in rabbits.
    Saettone MF; Chetoni P; Cappanera L; Conte U; Finne U; Järvinen K; Salivirta J; Urtti A
    J Ocul Pharmacol; 1993; 9(1):1-12. PubMed ID: 8463729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Light-dark variations in ocular timolol concentrations following topical solution instillation in the pigmented rabbit.
    Ohdo S; Zhu J; Lee VH
    Life Sci; 1992; 51(26):2025-31. PubMed ID: 1474859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular mini-tablets for controlled release of timolol: evaluation in rabbits.
    Chetoni P; Mariotti Bianchi L; Giannaccini B; Saettone MF; Conte U; Sangalli ME
    J Ocul Pharmacol Ther; 1996; 12(3):245-52. PubMed ID: 8875330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration and long-term efficacy of phenylephrine-induced reduction in the systemic absorption of ophthalmic timolol in rabbits.
    Järvinen K; Urtti A
    J Ocul Pharmacol; 1992; 8(2):91-8. PubMed ID: 1506759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the ocular to systemic ratio of topical timolol by varying the dosing time.
    Ohdo S; Grass GM; Lee VH
    Invest Ophthalmol Vis Sci; 1991 Sep; 32(10):2790-8. PubMed ID: 1894477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of concentration-time profiles of levobunolol and timolol in anterior and posterior ocular tissues of albino rabbits.
    Acheampong AA; Breau A; Shackleton M; Luo W; Lam S; Tang-Liu DD
    J Ocul Pharmacol Ther; 1995; 11(4):489-502. PubMed ID: 8574812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular pharmacokinetics of atenolol, timolol and betaxolol cocktail: Tissue exposures in the rabbit eye.
    Fayyaz A; Vellonen KS; Ranta VP; Toropainen E; Reinisalo M; Valtari A; Puranen J; Ricci GD; Heikkinen EM; Gardner I; Ruponen M; Urtti A; Jamei M; Del Amo EM
    Eur J Pharm Biopharm; 2021 Sep; 166():155-162. PubMed ID: 34139290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular release of timolol from molecularly imprinted soft contact lenses.
    Hiratani H; Fujiwara A; Tamiya Y; Mizutani Y; Alvarez-Lorenzo C
    Biomaterials; 2005 Apr; 26(11):1293-8. PubMed ID: 15475059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic basis for nonadditivity of intraocular pressure lowering in timolol combinations.
    Lee VH; Luo AM; Li SY; Podder SK; Chang JS; Ohdo S; Grass GM
    Invest Ophthalmol Vis Sci; 1991 Oct; 32(11):2948-57. PubMed ID: 1917398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basis for dosing time-dependent changes in the ocular and systemic absorption of topically applied timolol.
    Lee VH; Yamahara H; Gurny R; Sintzel MB; Martenet M; Gex-Fabry M; Balant L; Ohdo S; Podder SK
    J Ocul Pharmacol Ther; 1996; 12(2):103-13. PubMed ID: 8773926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative distribution of pilocarpine in ocular tissues of the rabbit during administration by eyedrop or by membrane-controlled delivery systems.
    Sendelbeck L; Moore D; Urquhart J
    Am J Ophthalmol; 1975 Aug; 80(2):274-83. PubMed ID: 1155567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theoretical corneal permeation model for ionizable drugs.
    Friedrich SW; Cheng YL; Saville BA
    J Ocul Pharmacol; 1993; 9(3):229-49. PubMed ID: 8228531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes.
    Chiang CH; Ho JI; Chen JL
    J Ocul Pharmacol Ther; 1996; 12(4):471-80. PubMed ID: 8951683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of the noncorneal absorption route in topical ophthalmic drug delivery.
    Ahmed I; Patton TF
    Invest Ophthalmol Vis Sci; 1985 Apr; 26(4):584-7. PubMed ID: 3884542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.